PPD is expanding its cGMP cell-based assay lab in Middleton, WI to support a greater volume of bioassay development, validation and testing projects and provide a broader range of product testing capabilities.

“Biotech and pharmaceutical companies are shifting their strategies to develop high-value, niche therapies utilizing biologics, a trend that is expected to generate significant growth in characterization of biologics, as well as biosimilars,” said Magdalena Mejillano, Ph.D., vice president of cGMP labs for PPD. “Expanding our capabilities to perform additional cell-based assays that establish the potency and stability of these biologics gives clients greater capacity, flexibility and efficiency in testing their products.”